Treatment of Pulmonary Hypertension Secondary to Left Heart Disease in Heart Failure with Reduced Ejection Fraction (HFrEF)

This protocol covers pulmonary hypertension secondary to left heart disease specifically in patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%) or heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41–49%).

Clinical Scenario

The patient has pulmonary hypertension arising from left heart disease in the context of significantly impaired left ventricular function — either heart failure with reduced ejection fraction (LVEF ≤40%) or heart failure with mildly reduced ejection fraction (LVEF 41–49%). Management of the underlying left heart failure is central to this clinical picture.

Treatment Approach

Management in this population centres on guideline-directed treatment encompassing established medical and interventional therapies directed at the underlying heart failure. The specific therapies, sequencing, and decision points are defined in the full structured protocol.

Complete regimen details — including which therapies apply in this scenario — are available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehac237

Patients with HFrEF or HFmrEF require guideline-directed treat-ment including established medical and interventional therapies.

View source ↗